Posted: JUN 24, 2008

CSMG Technologies Subsidiary Live Tissue Connect Presents Its Bipolar Continuous Welding of Tissue at the 2008 Future Medical Forum

Corpus Christi, TX, June 24, 2008 -- CSMG Technologies, Inc., (OTCBB: CTGI - News), a technology management company, announced Mr. Frank D'Amelio, President of Live Tissue Connect (LTC), a subsidiary of CSMG Technologies, presented at the 2008 Virtus International Future Medical Forum in Tampa, Florida. This medical forum focuses on the impact new technologies and materials have on the discovery, development, and design of medical devices. The Future Medical Forum is a significant medical device event, as it brings together some of the leading minds and decision makers in the medical device industry for a two day conference.

Mr. Donald S. Robbins, President and CEO of CSMG Technologies, said, "We are pleased that LTC's President, Frank D'Amelio, has been invited back to the Future Medical Forum for a second consecutive year. Since last year, Live Tissue Connect has made significant technological advancements and is excited to introduce them to the world's leading medical organizations and ancillary support companies."

Live Tissue Connect's President, Frank D'Amelio commented, "Our presentation titled 'Tissue Fusion and Tissue Welding, a Replacement for Sutures and Staples?' was well received. LTC presented our recent clinical results and advances in the bipolar welding of tissue. We also compared LTC's welding results against those achieved by mechanical staples. LTC's continuous weld, non-foreign body technology has obtained high-quality clinical results in a recent animal study, and such is of great interest as an alternative to sutures and mechanical staples."

CSMG owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 31 patents in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT:

CSMG Technologies, Inc.
Donald S. Robbins, 361-887-7546
President and CEO
or
K. Bruce Jones, 770-955-0409